Cholesterol-lowering drugs: science and marketing.

about

Di'ao Xinxuekang Capsule, a Chinese Medicinal Product, Decreases Serum Lipids Levels in High-Fat Diet-Fed ApoE Mice by Downregulating PCSK9

P2860

Q59137753-B5A69B17-30F6-42B8-87B3-ACDECC339814

P2860

Cholesterol-lowering drugs: science and marketing.

Item

http://www.wikidata.org/entity/Q51193262

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Cholesterol-lowering drugs: science and marketing.

@en

Cholesterol-lowering drugs: science and marketing.

@nl

type

Item

label

Cholesterol-lowering drugs: science and marketing.

@en

Cholesterol-lowering drugs: science and marketing.

@nl

prefLabel

Cholesterol-lowering drugs: science and marketing.

@en

Cholesterol-lowering drugs: science and marketing.

@nl

P1476

Cholesterol-lowering drugs: science and marketing.

@en

P2093

Anna Padula

http://www.w3.org/2001/XMLSchema#string

Livio Garattini

http://www.w3.org/2001/XMLSchema#string

P2860

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

How do we improve patient compliance and adherence to long-term statin therapy?

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK

Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany.

Predictors of nonadherence to statins: a systematic review and meta-analysis.

P304

57-64

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0141076816681951

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28084157

http://www.w3.org/2001/XMLSchema#string

P932

5305008

http://www.w3.org/2001/XMLSchema#string

Cholesterol-lowering drugs: science and marketing.

about

P2860

P2860

Cholesterol-lowering drugs: science and marketing.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932